Clinical trials: Metformin
GLP-1；Metformin；Telomere-telomerase System；Par-4
Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment
Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.
- Trial name
- Par-4；GLP-1 (NCT02535299)
- Testing
- Liraglutide, Metformin
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Overweight Subjects, Metformin
Metformin Induces a Dietary Restriction-like State in Human
The fact that metformin treatment has been associated with reduced risk of cancer and cardiovascular disease raises the possibility of a beneficial role of metformin for other age-related diseases.
- Conditions
- Overweight Subjects, Metformin, Aging
- Trial name
- NCT02745886
- Testing
- metformin 0.85 twice daily for 6 months, Calorie restriction
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Xiang Guang-da
Metformin Response, Fasting Glucose
Dietary Intake of Tryptophan and Metformin Response
This study will examine the influence of dietary intake of tryptophan on response to metformin. The investigators hypothesize that dietary tryptophan alteration will influence metformin response.
- Conditions
- Metformin Response, Fasting Glucose, Tryptophan Concentration, Metformin Concentration
- Trial name
- NCT02184832
- Testing
- Metformin, Low tryptophan diet, High tryptophan diet
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes, Currently Taking Metformin
Using Continuous Glucose Monitoring to Understand the Glycemic Impact of Food
This study will look at the impact that meals have on blood glucose (sugar) levels. Subjects will be asked to use a Continuous Glucose Monitoring System (CGM), which monitors glucose levels continuously.
- Trial name
- NCT00818077
- Testing
- Continuous Glucose Monitoring of Carbohydrate Intake
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HealthPartners Institute
Pharmacogenetics of Metformin
The Inhibitory Effect of Metformin on Gluconeogenesis in Relation to Polymorphisms in Organic Cation Transporter 1
The aim of the study is to evaluate the pharmacodynamic impact of metformin in healthy Caucasian volunteers with and without single polymorphisms M420del or R61C in OCT1, thus the study hypothesis is that metformin only affect…
- Trial name
- NCT01400191
- Testing
- Metformin
- Where
- Denmark
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Lactic Acidosis, Metformin
Study On the Role of Mitochondrial Dysfunction in the Pathogenesis of Metformin-associated Lactic Acidosis
Metformin is the first line drug of choice for the treatment of type II diabetes. Lactic acidosis can develop as a side effect, especially when renal failure leads to drug accumulation.
- Trial name
- NCT00942123
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Metformin
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin
The purpose of this study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of a single dose of metformin.
- Conditions
- Pharmacokinetics of Isavuconazole, Pharmacokinetics of Metformin, Healthy Subjects
- Trial name
- NCT01884558
- Testing
- isavuconazole, metformin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Metformin XR BE Study in Healthy Volunteers With Single and Multiple Dose
Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet
This was a single centre, single-blind, randomized, balanced, combined single dose study under fasting condition and multiple doses study under fed condition with normal diabetic-meal, two-period, two-sequence cross-over study to…
- Trial name
- NCT01677260
- Testing
- 500 mg metformin hydrochloride extended release caplet (test drug), 500 mg metformin hydrochloride prolonged release tablet (reference drug)
- Where
- Indonesia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc
Study in healthy subjects to measure amount of drug in blood after dosing with different saxagliptin / metformin products.
- Trial name
- NCT01441869
- Testing
- Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Metformin, Organic Cation Transporter 2
A Pharmacokinetic Evaluation of Metformin in Relation to the Polymorphism A270S in Healthy Caucasian Volunteers
The aim of the study is to evaluate the pharmacokinetics of metformin in healthy Caucasians volunteers with and without the polymorphism A270S in OCT2,thus the study hypothesis is that renal clearance of metformin is affected in…
- Conditions
- Metformin, Organic Cation Transporter 2, Polymorphism,Single Nucleotide
- Trial name
- NCT01237522
- Testing
- Metformin
- Where
- Denmark
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in
A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is a chronic metabolic disorder which is caused by both insulin secretion deficiency and insulin action defect.
- Conditions
- The Objectives of the Study is to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg, Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 mg Thrice Daily Over 16 Weeks in, Subjects With Type 2 Diabetes Mellitus.
- Trial name
- NCT01245166
- Testing
- Acarbose, Metformin/Acarbose
- Where
- Taiwan
- Volunteers
- 220 people
- Sponsor
- Lotus Pharmaceutical